🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Another fantastic & dedicated group of medical oncologists & oncology nurses at this year's Masterclass #19MCO, #19MON

Everolimus vs Alpelisib, who wins? In the #COVID19 days, our work on cancer research goes on! BMC …ast-cancer-research.biomedcentral.com/articles/10.11…

Super proud of my friends Federico Nichetti Francesca Ligorio who yesterday received the prestigious young research award at Istituto Tumori

Just out 😀 meta-analysis investigating outcome of patients with m+ tumors who discontinued ICIs not for PD. happy to be part of this work thelancet.com/journals/eclin…

Super happy to have had the opportunity to attend SABCS 2024, which has been amazing!☆Here with the poster of our meta-analysis, showing that benefit from novel breast cancer drugs of the last decade is not ethnicity dependent! Angela Toss

happy to be part of this work! thank you Pier Paolo Berton Giachetti and all the coauthors

Truly honored to be among the recipients of the #ASCO2025 Conquer Cancer Merit Award. Grateful for the support of Angela Toss, all PAMBRACA study collaborators, and the patients who inspire our research every day. See you in Chicago!!✴️

A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!

Our paper on breast cancer prognosis in European AYAs (15–39 y) just published in The Breast Online! Angela Toss Fedro Peccatori MD, PhD 🔹 Worse breast cancer survival for AYAs vs. older women 🔹 Similar stage at diagnosis 🔹 ~6% get a second cancer within 14 yrs thebreastonline.com/article/S0960-…

#ASCO2025 Poster presentation today: results of our Italian multicenter real-world PAMBRACA study. As first post-CDK4/6i line, PARPi associated with ⬆️rwPFS vs. ET or chemo in BRCA-associated HR+/HER2- aBC. No prior data on PARPi after CDK4/6i PD available before.